Dermatologic Applications of Rituximab

rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestationJanda PH, Bhambri S, Del Rosso JQ, rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestation

rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestationJanda PH, Bhambri S, Del Rosso JQ, rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestation

rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestationJanda PH, Bhambri S, Del Rosso JQ, rituximab, antibody, CD20, B-cell lymphoma, pemphigus vulgaris, atopic dermatitis, vasculitides, epidermolysis bullosa acquisita, cryoglobulinemia, dermatomyositis, chronic graft, hot disease, immunoglobuiln, murine varible region, human constant region, Fab fragment, Fc fragment, plasma cells, acute GVH disease, angioedema, atopic eczema, chronic GVH disease, bullous pemphigoid, immunobullous disease, mucous membrane, paraneoplastic, scleroderma, lupus, vitiligo, Churg-Strauss syndrome, autoantibodies, violaceous poikiloderma, heliotrope rash, musculoskeletal manifestation